Clínica Médica
Revisão da prática atual | Prevenção e tratamento de íleo pós-operatório.
14 Abr, 2022 | 16:24hPrevention and Management of Postoperative Ileus: A Review of Current Practice – Cureus
Diretriz preliminar NICE recomenda manter a circunferência da cintura menor do que metade da altura.
12 Abr, 2022 | 12:50hComentários:
Keep your waist to less than half your height, guidance says – BBC
Diretriz preliminar: Obesity: identification and classification of overweight and obesity – National Institute for Health and Care Excellence
Atualização clínica sobre COVID-19 para o médico da emergência e terapia intensiva.
12 Abr, 2022 | 12:49hRevisão | Fibrilação atrial.
12 Abr, 2022 | 12:46hAtrial fibrillation – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)
Infográfico: Atrial fibrillation – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)
Comentário no Twitter
Get Primed on Atrial fibrillation with our NEW PrimeView! FREE to download this week! #AtrialFibrillation #AFibhttps://t.co/sI8Gx3yHmk pic.twitter.com/r6heFStAz5
— Nature Reviews Disease Primers (@DiseasePrimers) April 7, 2022
Estudo randomizado | Para adultos vivendo com HIV, uma estratégia de tratamento de 4-dias-sim e 3-dias-não é não inferior ao tratamento padrão para manter a supressão viral.
12 Abr, 2022 | 12:45hA 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link para o resumo – $ para o texto completo)
Comentário: Intermittent Treatment Strategy Is Effective for HIV – Consultant360
Comentário no Twitter
New: A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Roland Landman and colleagues https://t.co/Tc2Rbo1ISt pic.twitter.com/YTV3XwfELo
— The Lancet HIV (@TheLancetHIV) February 3, 2022
In virologically suppressed people with HIV, randomization to intermittent ART (4 days on, 3 off) was non-inf. to daily dosing. Challenges what I thought about level of adherence needed. Is good adherence only needed during the viremic phase? https://t.co/lM8QZW0C9h
— David Serota (@serotavirus) March 16, 2022
Revisão | Síndrome gastrintestinal pós-COVID-19 aguda.
12 Abr, 2022 | 12:43hGastrointestinal post-acute COVID-19 syndrome – Nature Reviews Gastroenterology & Hepatology
Comentário no Twitter
NEW! COMMENT
Gastrointestinal post-acute COVID-19 syndromehttps://t.co/SDAOnQSEp4#COVID19 #LongCovid pic.twitter.com/CUSoUt0azy
— Nature Reviews Gastroenterology & Hepatology (@NatRevGastroHep) April 9, 2022
Estudo randomizado | Efeito da antibioticoterapia inicial guiada por coloração de Gram sobre a resposta clínica de pacientes com pneumonia associada a ventilador.
12 Abr, 2022 | 12:35hComentário: Can Gram Stains Guide Antibiotics for Pneumonia in Critical Care? – Medscape (necessário cadastro gratuito)
Comentário no Twitter
RCT found gram stain-guided antibiotic therapy for critically ill patients with VAP was noninferior to guideline-based antibiotics, with a reduction in antipseudomonal & antiMRSA use. https://t.co/1yoHO2pnER
— JAMA Network Open (@JAMANetworkOpen) April 8, 2022
Diretriz clínica do Reino Unido para prevenção e tratamento de osteoporose.
12 Abr, 2022 | 12:33hUK clinical guideline for the prevention and treatment of osteoporosis – Archives of Osteoporosis
Sinopse de diretriz | Tratamento da doença multissintoma crônica.
12 Abr, 2022 | 12:24hEstudo randomizado | Eficácia e segurança do gefapixante, um antagonista donreceptor de P2X3, na tosse crônica refratária e na tosse crônica inexplicada.
12 Abr, 2022 | 12:17hEfficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
For refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice per day is the first treatment to show efficacy with an acceptable safety profile in phase 3 clinical trials.
New study by Lorcan P McGarvey & colleagues: https://t.co/XnWM75s6lN pic.twitter.com/VyYyRgWTod
— The Lancet (@TheLancet) March 7, 2022